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Abstract
Background—Endoscopic screening for esophageal neoplasia can identify patients eligible for
early intervention for pre-cancerous lesions. Unsedated transnasal esophagoscopy may provide an
efficient and accurate endoscopic assessment with fewer risks and less cost compared to
conventional upper endoscopy.
Objective—To assess the feasibility, safety, acceptability and yield of unsedated transnasal
esophagoscopy in a primary care population.
Design—Multi-center, prospective, cross-sectional study.
Setting—Two outpatient tertiary centers.
Patients—General medical clinic population between the ages of 40 and 85.
Interventions—Unsedated, office-based transnasal esophagoscopy.
Main outcomes measurements—1) Procedure yield, 2) Completeness of examination, 3)
Procedure length, 4) Adverse events and complications, 5) Choking, gagging, pain or anxiety
during the examination, and 6) Overall tolerability
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Results—Four hundred and twenty-six participants (mean age 55.8 ± 9.5, 43% male) enrolled in
the study, and 422 (99%) completed the examination. Mean examination time was 3.7 ± 1.8
minutes. There were no serious adverse events and 12 participants (2.8%) reported minor
complications. Participants reported minimal choking, gagging, pain or anxiety. The examination
was well tolerated by most participants. Overall, 38% of subjects had an esophageal finding that
changed management (34% erosive esophagitis, 4% Barrett’s esophagus).
Limitations—Nonrandomized study; tertiary centers only; self-selected population with a large
proportion reporting esophageal symptoms.
Conclusions—Unsedated transnasal esophagoscopy is a feasible, safe, and well-tolerated
method to screen for esophageal disease in a primary care population. Endoscopic findings are
common in this patient population.
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Esophageal adenocarcinoma has undergone the most rapid increase in incidence of any
neoplasia in the United States in the last three decades.[1, 2] Although standard upper
endoscopy allows the identification of precancerous lesions or cancer of the esophagus, this
examination is commonly performed with conscious sedation and occasionally under
general anesthesia.[3] Conscious sedation is associated with substantial cost. The use of
sedation with endoscopy requires additional monitoring, nursing support, and a recovery
area. Conventional upper endoscopy with biopsies costs an estimated $866 based on Center
for Medicare and Medicaid Services data.[4] Beyond the direct costs associated with the
examination, sedation requires a temporary guardian to accompany the patient home, which
results in substantial indirect costs and sometimes a reluctance to undergo the procedure for
both the patient and guardian. Sedation is also associated with some risk. Among patients
undergoing upper endoscopy with conscious sedation, the incidence of cardiopulmonary
events is estimated at 0.6%.[3] Unsurprisingly, given the substantial cost burden and
inconvenience associated with standard sedated upper endoscopy, most subjects who
develop esophageal adenocarcinoma have not previously been screened, nor had a
precancerous lesion identified.[5]
Unsedated small-caliber transnasal esophagoscopy offers the possibility of efficient and
accurate endoscopic assessment of the esophagus with less cost and fewer risks compared to
sedated upper endoscopy.[6–16] The sensitivity of detecting esophageal abnormalities with
unsedated small-caliber esophagoscopy is comparable to conventional upper endoscopy.[7–
11] Although unsedated transnasal esophagoscopy is well tolerated in cultures less
accustomed to conscious sedation,[11, 17–20] studies in North America have been limited
by small sample sizes and have been performed in specialized populations selected for either
esophageal symptoms or Barrett’s esophagus.[9, 10] Moreover, most studies in the U.S.
have been limited to selected populations in referral settings.
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The aim of this study was to assess the feasibility, safety, acceptability and yield of
unsedated transnasal esophagoscopy in the general medical outpatient setting as a screening
method for esophageal disease.
Methods
Study Design and Subjects
We performed a prospective, cross-sectional study of unsedated, office-based transnasal
esophagoscopy in two outpatient centers between 2009–2010. Participants were recruited
from the general medical clinic populations using flyers and e-mail announcements. We
included participants between the ages of 40 and 85, regardless of GERD symptomatology.
We excluded those with a history of anti-reflux surgery, esophageal diverticula or varices,
cirrhosis, head and neck or esophageal malignancy, recurrent epistaxis, previously
diagnosed Barrett’s esophagus, or New York Heath Association Class IV congestive heart
failure. Additionally, we excluded anyone with an active pulmonary or sinus infection,
recent ENT surgery, participants currently pregnant, on anticoagulation or with an oxygen
requirement. All participants gave informed consent. The Institutional Review Boards of
both centers approved the study.
Endoscopic Examination
Examinations were performed using the one-wheel TNE-5000 endoscope system, a 650 mm
video endoscope with a 120 degree field of view, encased in a disposable sheath of 4.7 mm
diameter (Vision Sciences, Orangeburg, NY) (Figure 1). Two endoscopists (BAJ, NJS)
experienced in transnasal upper esophagoscopy (>100 examinations before the study)
performed the examinations. A combination of a topical decongestant (oxymetazoline
hydrochloride, 0.05%, Afrin, Schering-Plough Healthcare Products, Inc., Memphis,
Tennessee) and topical anesthesia with 4% lidocaine was used to anesthetize the nares and
posterior pharynx. Topical anesthetic was delivered to the nares with a disposable atomizer
(Wolfe Tory Medical, Salt Lake City, UT) over a 5–10 minute period. Examinations were
performed with the participant in the sitting position. The posterior pharynx, esophagus and
proximal stomach were examined and biopsies were taken with forceps through a coaxial
channel in the sheath as noted below. Upper esophageal sphincter intubation was facilitated
by asking the subject to ingest water through a straw with scope advancement. The
examination was performed to the mid-stomach, and scope retroflexion was performed to
examine the cardia. After removal of the endoscope, the disposable sheath was stripped, and
the endoscope was wiped with an alcohol swab. The endoscope was then re-sheathed for the
next patient (for more details, see the video in the Supplementary Appendix).
When identified, the length of Barrett’s esophagus was measured in centimeters from the
most proximal extent of the gastric folds to the most proximal squamocolumnar junction
(SCJ). The presence of a hiatal hernia was documented and measured at the nares in
centimeters beginning at the crural pinch distally to the most proximal extent of the gastric
folds. Additionally, we evaluated the SCJ using the z-line appearance (ZAP) classification
scheme.[21] A sharp and circular SCJ without tongues of endoscopically visible columnar
epithelium denoted grade 0. Patients with Grade 0 ZAP classification were considered
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negative for BE. Grade I ZAP meant the Z line was irregular with tongue-like protrusions or
islands; grade II was present when obvious tongues of columnar epithelium <3 cm were
noted, and grade III, distinct tongues of columnar epithelium >3 cm, or a cephalad
displacement of the squamocolumnar junction > 3 cm. Four-quadrant esophageal biopsies
with a 1.8 mm needle forceps (Olympus, PA) were obtained beginning immediately
proximal to the top of the gastric folds and extending every 2 cm to the level of the
squamocolumnar junction for all patients with ZAP Grades I–III. Biopsies were fixed in
formalin, routinely processed, stained with hematoxylin and eosin (H&E), and interpreted
by an expert pathologist using standardized criteria.[22] The diagnosis of Barrett’s
esophagus required a ZAP score >0, as well as histological confirmation of the presence of
specialized intestinal metaplasia. The presence of esophagitis was documented and graded
using the Los Angeles Classification.[23]
A research assistant observed each esophagoscopy . The research assistant documented
completion of the examination and if not completed, the reason for discontinuation, the
length of the procedure, endoscopic findings as dictated by the endoscopist, and any adverse
events or complications. After the examination, participants completed a 10-question
assessment to measure procedure acceptability (Figure 2).
Data Collection and Analysis
For each subject, the following variables were collected: age, sex, race, height, weight,
education, current alcohol use (yes/no), history of tobacco use (yes/no), a gastroesophageal
reflux disease health related quality of life instrument,[24] the reflux symptom index score,
[25] medication use, co-morbidities, family history of Barrett’s esophagus, family history of
esophageal cancer, esophageal symptoms, completeness of the endoscopic examination, and
if not, why, procedure time, adverse events or complications, endoscopic findings, biopsy
results (if obtained), and patient reported acceptability. Potential GERD signs and symptoms
assessed included acid reflux, heartburn, chest pain, hoarseness, chronic sore throat, excess
mucus in nose or throat, chronic sinusitis, chronic bronchitis, chronic throat clearing,
difficulty swallowing, pain with swallowing, vomiting blood, and globus.
Our primary outcome variables were: 1) procedure yield, defined as the proportion of
subjects noted to have esophageal disease, including erosive esophagitis, Barrett’s
esophagus, esophageal nodules or mass, or esophageal cancer; 2) completeness of the
examination (treated as a binary variable, with a complete examination considered one
where visualization was carried through to the mid-stomach); 3) Procedure length, measured
in minutes from scope insertion into the nare to complete withdrawal; 4) adverse events and
complications, such as epistaxis, dizziness, syncope or near-syncope, and gastrointestinal
bleeding; 5) choking, gagging, pain and anxiety during the examination, using a
standardized questionnaire (figure 2); and overall tolerability, measured on a 1–10 scale,
with 1 being well-tolerated and 10 being poorly tolerated. Exploratory data analysis was
performed to examine the distribution of continuous and categorical values, and to
determine missing or implausible values. Bivariate analysis was then performed to identify
variables associated with 1) risk factors for poor tolerability of the endoscopic examination,
2) risk factors for erosive esophagitis and 3) risk factors for the combined outcome of
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erosive esophagitis and Barrett’s esophagus. Bivariate analysis was performed using
Student’s t-tests for continuous variables, and Pearson’s Chi-squared tests or Fisher’s exact
tests for categorical variables. Means and standard deviations were reported for continuous
variables. Medians and interquartile ranges were reported for continuous variables with
skewed distributions. Proportions were reported for categorical data.
Multiple linear regression using maximum likelihood ratio techniques was used to assess
risk factors for lower overall tolerability of the endoscopic examination. To construct these
models, we used non-collinear variables significantly related to the outcome in bivariate
analyses using p value of ≤0.1, and limiting the model to M/10 components (beta
coefficients + intercept), where M=[3*(n1)(n2)]/n (where n1 and n2 are the number of
subjects in each group, and n is the total number of subjects). Lower overall tolerability was
defined as a score of 3 or higher on the 1–10 Likert scale (>75th % percentile). Potential
predictor variables assessed in this model included: sex, age, race, BMI, alcohol use,
tobacco use, gastroesophageal reflux disease health related quality of life score, reflux
symptom index score, acid reflux, heartburn, dysphagia, odynophagia, chest pain,
hoarseness, chronic sore throat, excess mucous in the nose or throat, chronic sinusitis,
hematemesis, globus, unintentional weight loss, and feeling of something in the back of the
throat. The initial model was created with variables that were significantly associated with
lower overall tolerability in a bivariate analysis. The model was reduced using likelihood
ratio tests on non-significant variables.
Multiple linear regression was also used to assess risk factors for erosive esophagitis, as well
as the combined outcome of erosive esophagitis and Barrett’s esophagus. We considered all
of the variables detailed in the prior model in addition to NSAID, aspirin, proton pump
inhibitor and H2 receptor antagonist use. The model was created and reduced using the
methodology detailed above.
All tests of significance were two-tailed and p-values <0.05 were considered significant. All
data were entered into and analyzed using Stata 11.0 statistical software (StataCorp, College
Station, TX).
Results
A total of 426 participants were enrolled in the study. The mean age was 55.8 ± 9.5 years
and 43% were male (Table 1). The mean BMI was 28.0 ± 6.1. Other characteristics of the
cohort are reported in table 1.
The majority (70%) of participants reported reflux or heartburn symptoms. Almost a third
(29%) reported excess mucus in the nose or throat and a quarter reported (25%) hoarseness.
Approximately, a fifth of participants reported globus (20%), chronic throat clearing (20%),
chest pain (19%), or dysphagia (18%). Finally, 13% reported chronic sinusitis, 7% chronic
sore throat, and 5% odynophagia.
A large proportion of our population had significant endoscopic findings on examination
(Table 2). A third (34%) of participants had erosive esophagitis (51% LA Grade A, 32% LA
Grade B, 13% LA Grade C, 2% LA Grade D). Bivariate analysis demonstrated that erosive
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esophagitis was associated with male sex, heartburn symptoms and not taking a PPI or
H2RA (Table 3). Eighteen participants (4%) were diagnosed with Barrett’s esophagus.
Almost half (n=180, 43%) of participants had a hiatal hernia. Twelve participants (3%) were
found to have an esophageal nodule. All were referred for further evaluation with
conventional upper endoscopy. Of the twelve participants, four have had an upper
endoscopy, five have an upper endoscopy pending and three have yet to schedule follow up.
Of the four participants with an esophageal nodule who underwent upper endoscopy, one
was found to have intestinal metaplasia with high-grade dysplasia and the rest had
nonneoplastic lesions.
In multivariate analysis, predictors of erosive esophagitis included male sex (OR 2.7, 95%
CI 1.7–4.2), heartburn symptoms (OR 1.5, 95% CI 0.97–2.4), the presence of a hiatal hernia
(OR 3.7, 95% CI 2.4–5.8), and non-use of a PPI or H2RA (OR 0.57, 95% CI 0.37–0.90)
(Supplementary Table 1). The combined outcome of erosive esophagitis and Barrett’s
esophagus was similarly predicted by male sex (OR 2.9, 95% CI 1.8–4.5), heartburn
symptoms (OR 1.6, 95% CI 1.0–2.5), the presence of a hiatal hernia (OR 3.8, 95% CI 2.4–
6.0), and non-use of a PPI or H2RA (OR 0.57, 95% CI 0.36–0.89).
Feasibility and Safety
Of the 426 subjects who enrolled in the study, 422 (99%) completed the examination. Four
participants discontinued the examination secondary to nasal discomfort with insertion of
the endoscope. The mean examination time was 3.7 ± 1.8 minutes (3.3 ± 1.6 minutes
without esophageal biopsies and 4.8 ± 1.7 minutes with esophageal biopsies (p<0.001)).
No subject experienced a serious adverse event. Twelve participants (2.8%) developed a
minor complication. Minor complications included lightheadedness (n=7, 1.6%), self-
limited epistaxis (n=3, 0.7%), nausea (n=2, 0.4%), headache (n=1, 0.2%) and nasal irritation
(n=1, 0.2%).
Acceptability Analysis
Participants reported minimal anxiety, pain, gagging or choking with insertion of the
endoscope or during the procedure (Table 3). Participants reported minimal anxiety before
the endoscopy. Overall, most participants reported that the procedure was well tolerated.
Lower overall tolerability was associated with female sex and younger age in a bivariate
analysis (Supplementary Table 2). In multivariate analysis, lower overall tolerability was
predicted by female sex (OR 1.7, 95% CI 1.1–2.8) and younger age (age < 50, OR 2.0, 95%
CI 1.2–3.2).
Discussion
Our study demonstrates that unsedated trans-nasal esophagoscopy is both feasible and safe
in a primary care population, achieving short procedure times, a high diagnostic yield and
minimal anxiety. Patients reported good acceptability and minimal discomfort. Male sex,
heartburn symptoms, a hiatal hernia, and non-use of PPI’s were predictors of erosive
esophagitis in this patient population.
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Our study is the largest reported experience with transnasal esophagoscopy in the United
States. Four studies have assessed unsedated small-caliber transnasal esophagoscopy in
North America.[7, 9, 10, 20] In general, these studies demonstrate that transnasal
esophagoscopy is well tolerated. However, these studies are limited by small sample sizes
and/or specialized populations with a history of esophageal symptoms or Barrett’s
esophagus. Studies assessing concordance rates between transnasal esophagoscopy and
standard endoscopy demonstrate moderate to good agreement in findings between the two
techniques. [7–11]
Unlike prior studies, our research was a prospective evaluation of a large group of general
medical clinic patients. , We began with well-defined study outcomes, including a complete
assessment of potential complications and a detailed questionnaire to assess procedure
acceptability. Standardized methods were used to assess symptom burden and endoscopic
findings. Study limitations included a self-selected populations recruited in two centers. A
large proportion of these subjects had symptoms of heartburn or reflux and may therefore
have had a lower threshold for procedure acceptability. Subjects were recruited in academic
centers and may differ in important ways from the general community. Because two
endoscopists with extensive experience in transnasal esophagoscopy performed the
examinations, it is possible that patient tolerability would be lower with less experienced
endoscopists.
Although the primary goal of these examinations was to screen for esophageal disease, it is
important to note that distal stomach or proximal duodenum pathology might not be detected
with the examination described here.. For subjects with a concern for distal gastric or
duodenal disorders, this particular endoscopic approach would not be appropriate.
Although transnasal esophagoscopy has been available for more than a decade, the
technique has not been widely used in practice. Physician concerns may include safety,
patient tolerance, and uncertainty regarding the time and facilities required to complete the
examination. Training in the technique is not widely available, and criteria for training and
exam quality are not standardized. For endoscopists already performing standard upper
endoscopy, transnasal esophagoscopy may be viewed as a competing technology, with the
potential to decrease income by shifting full examinations performed in ambulatory care
centers to brief, office-based examinations.
Although these problems are substantial, significant data suggest that alternative screening
modalities for esophageal pathology are needed. Considerable concern regarding the cost-
effectiveness of upper endoscopy as a screening tool [26] has been further heightened by
recent data demonstrating that the risk of esophageal adenocarcinoma in the setting of
Barrett’s esophagus may be lower than previously estimated. [27, 28] Endoscopic screening
programs were long considered important because of their yield of newly-diagnosed cases of
Barrett’s esophagus, but a lower risk of cancer in Barrett’s raises the natural question of how
much we should value a Barrett’s screening test. Given the marked rise in the incidence of
adenocarcinoma of the esophagus in the last four decades, it seems unwise and illogical to
abandon upper endoscopic screening examinations entirely. Therefore, a technology with
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which to screen large numbers of subjects quickly and at a fraction of the cost of standard
endoscopy is attractive from a public health perspective.
Transnasal esophagoscopy might be a suitable candidate for this technology. Examinations
are short in duration, suggesting that the modality might be appropriate for wide scale
programs in primary care populations. This technique avoids many of the costs associated
with sedation, endoscope sterilization, and GI suite nursing. Because of the low cost of the
endoscope sheath used in this study ($40), and because the costs of the endoscope itself
could be amortized over many examinations, the overall cost profile of a screening program
using this technology would be expected to be much less than the current standard of care,
and would likely be sensitive to the program’s case volume. Further, if applied in a primary
care clinic population, transnasal esophagoscopy could be used in a population that might
otherwise go unexamined.
To date, no data are available to ascertain which healthcare providers should implement
transnasal esophagoscopy screening programs. Gastroenterologist and surgeon endoscopists
might be expected to require the least training, given their experience. However, a large
body of data documents the successful performance of other endoscopic procedures by
generalist physicians [29, 30] and even physician extenders [31] in other clinical settings.
Whether high quality, cost-effective screening programs might be implemented by these
providers remains to be demonstrated. By better defining quality metrics for such
examinations, rational training strategies might be developed for these practitioners.
In our study, both erosive esophagitis and the combined outcome of erosive esophagitis and
Barrett’s esophagus were predicted by male sex, the presence of a hiatal hernia, heartburn
symptoms, and absence of PPI or H2A therapy. These risk factors for acid-peptic esophageal
disease are consistent with studies using standard per oral endoscopy. Similarly, GERD
symptoms, hiatal hernia and male sex have been previously associated with Barrett’s
esophagus risk.[32–35] Although we did not assess concordance rates of transnasal
esophagoscopy and standard endoscopy in the current study, the presence of similar risk
factors for erosive esophagitis and Barrett’s esophagus suggests that transnasal
esophagoscopy is identifying patients with upper gastrointestinal pathology similar to those
identified by standard endoscopy in previous studies.
In conclusion, unsedated transnasal esophagoscopy is a safe and well-tolerated method to
screen for esophageal disease in a primary care population. In our population, screening
identified a significant number of abnormalities that might have otherwise gone undetected
until further progression of disease. Unsedated transnasal esophagoscopy may provide an
accurate, lower-cost alternative to standard endoscopy, and may allow for affordable
screening for general medical patients at risk for esophageal neoplasia or other esophageal
diseases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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One-wheel TNE-5000 video endoscope encased in 4.7 mm diameter disposable sheath
(Vision Sciences, Orangeburg, NY
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10-question assessment to measure procedure acceptability
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Reported esophageal symptoms and percentage found to have erosive esophagitis on
transnasal examination
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An image captured from a participant with intestinal metaplasia
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Table 1
Participant Characteristics
Characteristics (n = 426) Mean ± standard deviation or n (%)
Age, years 55.8 ± 9.5
Male 182(43)
White 359 (85)
BMI, kg/m2 28.0 ± 6.1
>16 years education 280 (66)
Alcohol use 298 (70)
History of tobacco use 217 1) (5
Reflux Symptom Index*† 5
GERD Health Related Quality of Life*‡ 3.5
Medication Use:
  Proton pump inhibitor 185 (44)
  H2 receptor antagonist 105 (25)
  NSAID use 148 (35)
  ASA use 163 (38)
Co-Morbidities:
  Asthma 27 (6)
  Allergies 154 (36)
  Diabetes 28 (7)
  Coronaryartery disease 6 (1)
  COPD 9 (2)
  Hypertension 113 (27)
  GERD 128 (30)
  Familyhistory of Barrett’s esophagus 16 (5)
  Familyhistory of esophageal cancer 45 (12)
*
Medians reported for skewed distributions
†
The reflux symptom index is graded on a 0 –45 scale with a score > 13 suggestive of laryngopharyngeal reflux
‡
GERD Health Related Quality of Life is graded ona 0–51 scale with higher scores suggestive of worse GERD symptom severity


























Erosive Esophagitis 143 (34)
  LAGradeA 73 (51)
  LAGradeB 46 (32)
  LAGradeC 18 (13)
  LA Grade D 3 (2)
Hiatal Hernia 180 (43)
Barrett’s Esophagus 18 (4)
Esophageal Mass/Nodularity Requiring Subsequent Endoscopic Resection 12 (3)
Gastritis 15 (4)
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Table 3
Participant Reported Acceptability
Characteristic Median (interquartile range)
Pain during insertion of the endoscope
[0= No pain,10= Severepain]
2 (2)
Pain during the procedure
[0= No pain,10= Sever pain]
2 (2)
Gagging or wretching during insertion of the endoscope
[0= No gagging, 10= Worst gagging]
2 (2)
Gagging or wretching during the procedure
[0= No gagging, 10= Worst gagging]
2 (2)
Choking during insertion of the endoscope
[0= No choking, 10= Worst choking]
1 (1)
Choking during the procedure
[0= No choking, 10= Worst choking]
1 (1)
Anxiety, nervousness or worried during insertion of the endoscope
[0 = No worries, 10= I was terrified]
3 (3)
Anxiety, nervousness or worried during the procedure
[0 = No worries, 10= I was terrified]
2 (3)
Anxiety, nervousness or worried before having the endoscopy
[0 = No worries, 10= I was terrified]
2 (3)
Overall, procedure tolerability
[0 = Well-tolerated, 10= Poorly tolerated]
1 (2)
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